UA129533C2 - Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo - Google Patents

Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo Download PDF

Info

Publication number
UA129533C2
UA129533C2 UAA201905231A UAA201905231A UA129533C2 UA 129533 C2 UA129533 C2 UA 129533C2 UA A201905231 A UAA201905231 A UA A201905231A UA A201905231 A UAA201905231 A UA A201905231A UA 129533 C2 UA129533 C2 UA 129533C2
Authority
UA
Ukraine
Prior art keywords
luciferase
protein
neurotoxin
chain polypeptide
cleavage site
Prior art date
Application number
UAA201905231A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мінь Дун
Минь ДУН
Фейфань Юй
Original Assignee
Презідент Енд Феллоуз Оф Гарвард Колледж
Президент Энд Феллоуз Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Презідент Енд Феллоуз Оф Гарвард Колледж, Президент Энд Феллоуз Оф Гарвард Колледж filed Critical Презідент Енд Феллоуз Оф Гарвард Колледж
Publication of UA129533C2 publication Critical patent/UA129533C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0069Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UAA201905231A 2016-10-20 2017-10-19 Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo UA129533C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410558P 2016-10-20 2016-10-20
PCT/US2017/057411 WO2018075783A2 (en) 2016-10-20 2017-10-19 In vitro and cell based assays for measuring the activity of botulinum neurotoxins

Publications (1)

Publication Number Publication Date
UA129533C2 true UA129533C2 (uk) 2025-05-28

Family

ID=60413254

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201905231A UA129533C2 (uk) 2016-10-20 2017-10-19 Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo

Country Status (21)

Country Link
US (2) US11306347B2 (enExample)
EP (1) EP3529616B1 (enExample)
JP (2) JP7227901B2 (enExample)
KR (1) KR102556363B1 (enExample)
CN (1) CN110088624B (enExample)
AU (1) AU2017345560C1 (enExample)
BR (1) BR112019007831A2 (enExample)
CA (1) CA3040507A1 (enExample)
DK (1) DK3529616T5 (enExample)
EA (1) EA039761B1 (enExample)
ES (1) ES2963830T3 (enExample)
FI (1) FI3529616T3 (enExample)
HU (1) HUE064332T2 (enExample)
MX (2) MX2019004431A (enExample)
PL (1) PL3529616T3 (enExample)
PT (1) PT3529616T (enExample)
SA (1) SA519401607B1 (enExample)
SG (1) SG11201903523YA (enExample)
UA (1) UA129533C2 (enExample)
WO (1) WO2018075783A2 (enExample)
ZA (1) ZA201902654B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6088438B2 (ja) 2010-12-22 2017-03-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 連続的定向進化
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
SG11201803173VA (en) 2015-10-23 2018-05-30 Harvard College Nucleobase editors and uses thereof
US11242515B2 (en) * 2016-05-16 2022-02-08 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
MX2019004431A (es) 2016-10-20 2019-08-14 Harvard College Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas.
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
AU2018321405A1 (en) 2017-08-25 2020-03-05 Ipsen Biopharm Ltd. Evolution of BoNT peptidases
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2021011579A1 (en) * 2019-07-15 2021-01-21 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
WO2021195479A1 (en) * 2020-03-26 2021-09-30 Cellex, Inc. Protease assays and their applications
CN114540419A (zh) * 2022-03-04 2022-05-27 中国人民解放军军事科学院军事医学研究院 一种分析包膜病毒膜融合效率的三功能报告系统
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
CN121057740A (zh) * 2023-04-21 2025-12-02 深圳琅技生命科技有限公司 一种肽以及含有该肽的发光复合物
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
CN119039432B (zh) * 2024-10-31 2025-01-28 兰州生物技术开发有限公司 一种检测肉毒毒素活性或突触体相关蛋白的方法和试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4950588A (en) 1985-07-10 1990-08-21 Molecular Diagnostics, Inc. Prolonged enhanced chemiluminescence
DE3537877A1 (de) 1985-10-24 1987-04-30 Geiger Reinhard Luciferin-derivate und immunoassays unter einsatz derartiger luciferin-derivate
US5004565A (en) 1986-07-17 1991-04-02 The Board Of Governors Of Wayne State University Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes
US5374534A (en) 1990-07-19 1994-12-20 Charm Sciences, Inc. Method of preparing D-luciferin derivatives
DE4210759A1 (de) 1992-04-01 1993-10-07 Boehringer Mannheim Gmbh Substituierte Thiazolin-Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung
DK0760681T3 (da) 1994-05-31 2000-03-27 Allergan Inc Modifikation af clostridielle toksiner til anvendelse som transportproteiner
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US6890745B1 (en) * 2000-07-19 2005-05-10 Chemicon International, Inc. Protease specific cleavable luciferases and methods of use thereof
CA2541765A1 (en) * 2003-10-10 2004-10-01 Promega Corporation Luciferase biosensor
US8753831B2 (en) 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
EP2456864B1 (en) 2009-05-01 2015-11-11 Promega Corporation Synthetic oplophorus luciferases with enhanced light output
US20140287433A1 (en) * 2011-07-19 2014-09-25 ETH Zürich Means and methods for determining clostridial neurotoxins
JP2015509372A (ja) 2012-03-07 2015-03-30 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 修飾ルシフェラーゼに基づいて神経毒活性を測定するための手段および方法
CN104736697B (zh) * 2012-10-16 2018-06-01 莫茨制药有限及两合公司 用于测定神经毒素多肽的生物学活性的细胞测试系统
JP2016502405A (ja) * 2012-11-21 2016-01-28 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー ボツリヌス神経毒の生物学的活性を決定するための手段及び方法
US9797889B2 (en) * 2013-03-15 2017-10-24 Promega Corporation Activation of bioluminescence by structural complementation
LT3014267T (lt) * 2013-06-28 2018-12-10 Merz Pharma Gmbh & Co. Kgaa Priemonės ir būdai, skirti neurotoksinių polipeptidų nustatymui
RU2746736C2 (ru) * 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
MX2019004431A (es) 2016-10-20 2019-08-14 Harvard College Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas.
PH12021551398A1 (en) * 2018-12-11 2022-11-07 Q32 Bio Inc Fusion protein constructs for complement associated disease

Also Published As

Publication number Publication date
EP3529616A2 (en) 2019-08-28
CA3040507A1 (en) 2018-04-26
US20190276873A1 (en) 2019-09-12
US11306347B2 (en) 2022-04-19
CN110088624A (zh) 2019-08-02
PL3529616T3 (pl) 2024-03-18
JP2023011700A (ja) 2023-01-24
HUE064332T2 (hu) 2024-03-28
AU2017345560C1 (en) 2025-04-17
US20220356508A1 (en) 2022-11-10
AU2017345560B2 (en) 2024-12-12
US11788069B2 (en) 2023-10-17
MX2023004733A (es) 2023-05-10
DK3529616T3 (da) 2023-12-11
ES2963830T3 (es) 2024-04-02
MX2019004431A (es) 2019-08-14
EA039761B1 (ru) 2022-03-10
DK3529616T5 (da) 2024-09-02
KR102556363B1 (ko) 2023-07-18
JP7227901B2 (ja) 2023-02-22
PT3529616T (pt) 2023-12-06
FI3529616T3 (fi) 2023-12-04
WO2018075783A2 (en) 2018-04-26
JP2019532651A (ja) 2019-11-14
EP3529616B1 (en) 2023-09-06
EA201990929A1 (ru) 2019-10-31
SG11201903523YA (en) 2019-05-30
KR20190068582A (ko) 2019-06-18
SA519401607B1 (ar) 2022-08-04
ZA201902654B (en) 2024-08-28
BR112019007831A2 (pt) 2019-10-01
AU2017345560A1 (en) 2019-05-02
CN110088624B (zh) 2024-01-16
WO2018075783A3 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
UA129533C2 (uk) Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo
US20210290682A1 (en) Functionalized Erythroid Cells
Aït-Ali et al. Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis
JP7305543B2 (ja) 組織特異的Wntシグナル増強分子およびその使用
CN105792840B (zh) 细胞
AU2018355462B9 (en) Recombinant immune cells, methods of making, and methods of use
JP5837917B2 (ja) エーリキア・カニスの免疫反応性糖タンパク質gp19
JP7427208B2 (ja) 視覚機能再生剤又は視覚機能低下予防剤
KR20200032722A (ko) 부분절단효소 내성 trem2 변이체
US11267874B2 (en) Sensor systems for target ligands and uses thereof
JPH08500737A (ja) グルカゴン・レセプタ
CN101160321A (zh) Q3 sparc缺失突变体及其用途
JP2020156498A (ja) 抗rho gtpaseコンホーメーションシングルドメイン抗体及びその使用
CN117777297B (zh) 抗内源性pink1蛋白的单克隆抗体及其应用
CA3119771A1 (en) Compositions and methods useful for targeting the blood-brain barrier
BRPI0611820A2 (pt) composição isolada, polinucleotìdeo e anticorpo isolado
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
UA120584C2 (uk) Варіантний інсектицидний ген axmi115 та способи його застосування
Hu et al. The Arg233Lys AQP0 mutation disturbs aquaporin0-calmodulin interaction causing polymorphic congenital cataract
AU2021207901A1 (en) IL2 orthologs and methods of use
JP2014001240A (ja) Ehrlichiachaffeensisにのためのワクチンおよび診断
JP2021518428A (ja) プログラム可能な免疫細胞受容体複合体システム
JP2023527026A (ja) 強化された合成t細胞受容体及び抗原受容体
CN109311950A (zh) 用于抑制wnt信号传导的组合物和方法
JPWO2012029958A1 (ja) 新たに同定したインスリン分泌制御因子を用いた抗糖尿病薬剤のスクリーニング法